<SEC-DOCUMENT>0001213900-24-061799.txt : 20240716
<SEC-HEADER>0001213900-24-061799.hdr.sgml : 20240716
<ACCEPTANCE-DATETIME>20240716163503
ACCESSION NUMBER:		0001213900-24-061799
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240716
FILED AS OF DATE:		20240716
DATE AS OF CHANGE:		20240716

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		241120041

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0209504-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer<BR>
Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of July 2024 (Report No. 3)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 16, 2024, SciSparc
Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification&rdquo;
announcing the receipt of a letter from the Nasdaq Stock Market LLC.&nbsp;A copy of this press release is furnished herewith as Exhibit
99.1 and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Report of Foreign Private
Issuer on Form 6-K is incorporated by reference into the registration statements on Form F-3 (File Nos. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390023018886/ea174796-posam_scisparc.htm">333-255408</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390023012516/ea172999-f3_scisparc.htm">333-269839</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390022037966/ea162219-f3_scisparcltd.htm">333-266047</A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390022022376/ea158932-posam_scisparcltd.htm">333-248670</A>, and <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390023088750/ea188733-f3a1_scisparc.htm">333-275305</A>) and on Form S-8 (File Nos. <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390024028880/ea0203015-s8_scisparc.htm">333-278437</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>) filed with the Securities and
Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or
reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT INDEX</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea020950401ex99-1_scisparc.htm">Press Release issued by SciSparc Ltd. on July 16, 2024 titled &ldquo;SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification&rdquo;.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SciSparc Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July 16, 2024</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1.5pt solid">/s/ Oz Adler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and<BR>
Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea020950401ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY SCISPARC LTD. ON JULY 16, 2024 TITLED "SCISPARC LTD. ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID PRICE NOTIFICATION"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><BR>
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">TEL AVIV, Israel, July
16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central nervous system (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;),
today announced it has received a written notice (the &ldquo;Notice&rdquo;) from Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) indicating
that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2),
which requires listed securities to maintain a minimum bid price of&nbsp;$1.00&nbsp;per share. Under Nasdaq Listing Rule 5810(c)(3)(A),
the Company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. The Notice has
no immediate effect on the Company&rsquo;s Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be
extended, the Company&rsquo;s ordinary shares will continue to trade on Nasdaq under the symbol &ldquo;SPRC&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">According to the Notice,
the Company has until&nbsp;January 13, 2025, to regain compliance with the minimum bid price requirement. The Company can regain compliance,
if at any time during this 180-day period, the closing bid price of its ordinary shares is at least&nbsp;$1.00&nbsp;for a minimum of ten
consecutive business days, in which case the Company will be provided with written confirmation of compliance and this matter will be
closed. In the event that the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for
an additional 180-day compliance period if it meets the continued listing requirement for market value of publicly held shares and all
other initial listing standards for The Nasdaq Capital Market, with the exception of the minimum bid price requirement. In this case,
the Company will need to provide written notice of its intention to cure the deficiency during the second compliance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If the Company cannot
demonstrate compliance by the allotted compliance period(s), Nasdaq&rsquo;s staff will notify the Company that its ordinary shares are
subject to delisting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About SciSparc Ltd. (Nasdaq:SPRC):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">SciSparc Ltd. is a specialty
clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc&rsquo;s focus is on creating
and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged
in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for
the treatment of Alzheimer&rsquo;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and
status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds&rsquo;
oil-based products on the Amazon.com Marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This press release contains
forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform
Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses regaining compliance
with Nasdaq&rsquo;s continued listing requirements, and timing and effect thereof. Because such actions deal with future events and are
based on the Company&rsquo;s current expectations, they are subject to various risks and uncertainties, and actual results, performance,
or achievements of the Company could differ materially from those described in or implied by the statements in this press release. Because
such statements deal with future events and are based on SciSparc&rsquo;s current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by
the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks
and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s Annual Report on Form 20-F
filed with the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;) on&nbsp;April 1, 2024, and in subsequent filings with the SEC.
Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B>IR@scisparc.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tel: +972-3-6167055</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "0 ) # 2(  A$! Q$!_\0
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M5(K&YD@M;Z**2#4M/EFABN%AG\MOL]]:M*C&&<0S.(KB+9*L<KA6 =@?QO\
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;PT.QT^SNM0U"X@DO)O>** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
